CAUTIONARY NOTE REGARDING FORWARDLOOKING STATEMENTS
This report, including the disclosures contained in Part I Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations, contains "forwardlooking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). These forwardlooking statements include, but are not limited to: any projections of net sales, earnings, or other financial items; any statements of the strategies, plans and objectives of management for future operations; expectations in connection with the Company's previously announced business optimization plan; any statements concerning proposed new products or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Forwardlooking statements can be identified by their use of such words as "may," "will," "estimate," "intend," "continue," "believe," "expect," or "anticipate" and similar references to future periods.
We have based our forwardlooking statements on management's current expectations and assumptions about future events and trends affecting our business and industry that are subject to risks and uncertainties. Although we do not make forwardlooking statements unless we believe we have a reasonable basis for doing so, we cannot guarantee their accuracy. Forwardlooking statements are subject to substantial risks and uncertainties that could cause our future business, financial condition, results of operations or performance to differ materially from our historical results or those expressed or implied in any forwardlooking statement contained in this report. These risks and uncertainties include, but are not limited to, uncertainties related to the broader economic environment affecting communities and businesses globally, including ours, as well as those factors described in the section "Risk Factors" included in Part I, Item 1A of our Annual Report on Form 10K for the fiscal year ended June 30, 2024, filed with the SEC, as well as in our other public filings with the SEC. Actual results may differ from projections as a result of these risks, additional risks and uncertainties of which we are currently unaware or which we do not currently view as material to our business.
You should read this report in its entirety, together with the documents that we file as exhibits to this report and the documents that we incorporate by reference into this report, with the understanding that our future results may be materially different from what we currently expect. The forwardlooking statements contained in this report are made as of the date of this report and we assume no obligation to update them after the date hereof to revise or conform such statements to actual results or to changes in our opinions or expectations. If we do update or correct any forwardlooking statements, investors should not conclude that we will make additional updates or corrections.
We qualify all of our forwardlooking statements by these cautionary statements.
The terms "we," "us," "Dynatronics," or the "Company" refer collectively to Dynatronics Corporation and its whollyowned subsidiaries, unless otherwise stated.
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations ("MD&A") is designed to provide a reader of our Unaudited Condensed Consolidated Financial Statements and Notes thereto that are contained in this quarterly report, with a narrative from the perspective of management. You should also consider this information with the information included in our Annual Report on Form 10K for the fiscal year ended June 30, 2024, and our other filings with the SEC, including our quarterly and current reports that we have filed since June 30, 2024 through the date of this report. In the following MD&A, we have rounded many numbers to the nearest one thousand dollars. These numbers should be read as approximate. All intercompany transactions have been eliminated. Our fiscal year ends on June 30. For example, reference to fiscal year 2025 refers to the year ending June 30, 2025. This report covers the three and six months ended December 31, 2024. Results of operations for the three and six months ended December 31, 2024 are not necessarily indicative of the results that may be achieved for the full fiscal year ending June 30, 2025.
Overview
Dynatronics is a leading medical device company committed to providing high-quality restorative products designed to accelerate achieving optimal health. The Company designs, manufactures, and sells a broad range of products for clinical use in physical therapy, rehabilitation, orthopedics, pain management, and athletic training. Through its distribution channels, Dynatronics markets and sells to orthopedists, physical therapists, chiropractors, athletic trainers, sports medicine practitioners, clinics, and hospitals. The Company's products are marketed under a portfolio of high-quality, well-known industry brands including Bird & Cronin, Solaris, Hausmann, PROTEAM, and Mammoth, among others. More information is available at www.dynatronics.com.
Results of Operations
Net Sales
Net sales decreased $851,000, or 10.4% to $7,300,000 for the quarter ended December 31, 2024, compared to net sales of $8,151,000 for the quarter ended December 31, 2023. Net sales decreased $2,601,000, or 14.9% to $14,902,000 for the six months ended December 31, 2024, compared to net sales of $17,503,000 for the six months ended December 31, 2023. The yearoveryear decrease is attributable to a reduction in overall volume for OEM customers and a general reduction in demand for the orthopedic soft bracing product category.
Gross Profit
Gross profit for the quarter ended December 31, 2024 decreased $175,000, or 9.6%, to $1,645,000, or 22.5% of net sales. By comparison, gross profit for the quarter ended December 31, 2023 was $1,820,000, or 22.3% of net sales. Gross profit for the six months ended December 31, 2024 decreased $501,000, or 12.1%, to $3,625,000, or 24.3% of net sales. By comparison, gross profit for the six months ended December 31, 2023 was $4,126,000, or 23.6% of net sales. The increase in gross profit as a percentage of net sales was driven primarily by higher product margin rates in our physical therapy and rehabilitation products, partially offset by the reduction in net sales as previously discussed.
Selling, General and Administrative Expenses
Selling, general and administrative ("SG&A") expenses decreased $411,000, or 15.1%, to $2,311,000 for the quarter ended December 31, 2024, compared to $2,722,000 for the quarter ended December 31, 2023. The decline in selling, general and administrative expenses was driven by a reduction in salaries and benefits, a decrease in sales expenses, and a reduction in other professional expenses.
SG&A expenses decreased $724,000, or 13.7%, to $4,543,000 for the six months ended December 31, 2024, compared to $5,267,000 for the six months ended December 31, 2023. The overall reduction in SG&A expenses was led by a reduction in salaries and benefits and decrease in sales and other professional expenses.
Net Other Expense
Net other expense for the quarter ended December 31, 2024, was $108,000 compared to net other expense of $110,000 for the quarter ended December 31, 2023. Net other expense for the six months ended December 31, 2024, was $215,000 compared to net other expense of $190,000 for the six months ended December 31, 2023.The year-over-year increase in net other expense for the six months ended December 31, 2024 is primarily due increased interest expense as a result of the Company's line of credit.
Income Tax Benefit (Provision)
Income tax benefit (provision) was $0 and $1,000 for the quarters ended December 31, 2024 and 2023, respectively, and ($9,000) and ($11,000) for the six months ended December 31, 2024 and 2023, respectively. See Liquidity and Capital Resources - Deferred Income Tax Assets below for more information.
Net Loss
Net loss for the quarter ended December 31, 2024 was $775,000 compared to a net loss of $1,011,000 for the quarter ended December 31, 2023. The $236,000 decrease in net loss was attributable a decrease of $411,000 in SG&A expenses and offset by a decrease in gross profit of $175,000.
Net loss for the six months ended December 31, 2024 was $1,141,000 compared to a net loss of $1,342,000 for the six months ended December 31, 2023. The $201,000 decrease in net loss was attributable to a decrease of $724,000 in SG&A expenses and decrease in the income tax provision of $2,000, offset by a decrease in gross profit of $501,000 and increase of $24,000 in net other expense.
Net Loss Attributable to Common Stockholders
Net loss attributable to common stockholders decreased $243,000 to $960,000 for the quarter ended December 31,2024 compared to $1,203,000 for the quarter ended December 31 2023. The decrease in net loss attributable to common stockholders for the quarter is due primarily to a $236,000 decrease in the net loss and a $6,000 decrease in the deemed dividends on convertible preferred stock and accretion of discounts. On a per share basis, basic and diluted net loss attributable to common stockholders was $0.13 per share for the quarter ended December 31, 2024, compared to $0.27 per share for the quarter ended December 31, 2023.
Net loss attributable to common stockholders decreased $235,000 to $1,495,000 for the six months ended December 31, 2024 compared to $1,730,000 for the six months ended December 31, 2023. The decrease in net loss attributable to common stockholders for the quarter is due primarily to a $201,000 decrease in the net loss and a $34,000 decrease in the deemed dividends on convertible preferred stock and accretion of discounts. On a per share basis, basic and diluted net loss attributable to common stockholders was $0.23 per share for the six months ended December 31, 2024, compared to $0.39 per share for the six months ended December 31, 2023.
Liquidity and Capital Resources
We have historically financed operations through cash from operating activities, available cash reserves, draws against the line of credit, and proceeds from the sale of our equity securities. As of December 31, 2024, we had $791,000 in cash and cash equivalents, compared to $484,000 as of June 30, 2024.
Working capital was $1,890,000 as of December 31, 2024, compared to working capital of $2,853,000 as of June 30, 2024. The current ratio was 1.2 to 1 as of December 31, 2024 and 1.4 to 1 as of June 30, 2024. Current assets were 43.1% of total assets as of December 31, 2024, and 40.7% of total assets as of June 30, 2024. These factors raised substantial doubt regarding the Company's ability to continue as a going concern as of December 31, 2024.
However, management is implementing plans to continue the Company as a going concern and believes that by focusing on cost-control initiatives the Company can continue as a going concern. The Company has reduced non-essential positions across the enterprise, resulting in a reduction in expense of approximately $400,000 for fiscal year 2025 and approximately $1,000,000 on an annualized basis. Additionally, management has optimized the square footage needed for the orthopedic bracing segment and is actively working to optimize the square footage footprint needed for the therapeutic modalities business segment, which could yield additional expense reductions of approximately $600,000 on an annualized basis. The Company is also evaluating the current inventory position and working to reduce the amount of excess inventory exposure by promoting discounted prices to convert the excess inventory to cash.
The Company has begun realizing the effects of these plans and expects continued effects to be realized in fiscal year 2025 and fiscal year 2026. Due to these actions, management forecasts that the Company will have sufficient liquidity to meet its obligations for the next twelve months from the date of the financial statements' issuance.
The continuing effects of uncertainties in the broader economic environment on the global supply chain, higher personnel costs, and changes to customer or product mix, could have an adverse effect on our liquidity and cash and we continue to evaluate and take action, as necessary, to preserve adequate liquidity and ensure that our business can continue to operate during these uncertain times. Additionally, we operate in a rapidly evolving and unpredictable business environment that may change the timing or amount of expected future cash receipts and expenditures. Accordingly, there can be no assurance that we will not be required to raise additional funds through the sale of equity or debt securities or from credit facilities. Additional capital, if needed, may not be available on satisfactory terms, or at all.
Line of Credit
On August 1, 2023, the Company entered into a Loan and Security Agreement (the "Loan Agreement") with Gibraltar Business Capital, LLC ("Lender"), to provide asset-based financing to the Company to be used for operating capital. Amounts available under the Loan Agreement (the "Revolving Loans") are subject to a borrowing base calculation of up to a maximum availability of $7,500,000 (the "Revolving Loan Commitment") and bear interest at SOFR plus 5.00%. The Company paid a closing fee of 1.00% of the Revolving Loan Commitment and the line is subject to a monthly unused line fee in an annualized amount equal to 0.50% on the difference between the Revolving Loan Commitment and the average outstanding principal balance of the Revolving Loans for such month. The maturity date is three years from the date of the promissory note evidencing the Revolving Loans, subject to extension in accordance with the terms of the Loan Agreement.
The Loan Agreement provides for revolving credit borrowings by the Company in an amount up to the lesser of the Revolving Loan Commitment and a borrowing base amount equal to the sum of stated percentages of eligible accounts receivable and inventory, less reserves, computed on a weekly basis.
The obligations of the Company under the Loan Agreement are secured by a first-priority security interest in substantially all of the assets of the Company (including, without limitation, accounts receivable, equipment, inventory and other goods, intellectual property, contract rights and other general intangibles, cash, deposit accounts, equity interests in subsidiaries and joint ventures, investment property, documents and instruments, and proceeds of the foregoing).
The Loan Agreement contains affirmative and negative covenants, including covenants that restrict the ability of the Company and its subsidiaries to, among other things, incur or guarantee indebtedness, incur liens, dispose of assets, engage in mergers and consolidations, make acquisitions or other investments, make changes in the nature of its business, and engage in transactions with affiliates. The Loan Agreement also contains financial covenants applicable to the Company and its subsidiaries, including a minimum fixed charge coverage ratio of 1.0 to 1.0 if excess availability is less than $1,000,000 of the borrowing base.
Cash and Cash Equivalents and Restricted Cash
Our cash and cash equivalents and restricted cash position increased $307,000 to $841,000 as of December 30, 2024, compared to $534,000 as of June 30, 2024. The primary source of cash for the six months ended December 31, 2024 was $233,000 of proceeds from the line of credit and $235,000 of cash provided by operating activities. The primary uses of cash included $149,000 of principal payments on finance lease liabilities and $11,000 of purchases of property and equipment.
Trade Accounts Receivable, net
Trade accounts receivable, net of allowance for credit losses, decreased approximately $621,000 or 18.0%, to $2,824,000 as of December 31, 2024, from $3,445,000 as of June 30, 2024. The decrease was driven primarily by a reduction in overall revenue and differences in the timing of collections around the end date of each respective quarter. Trade accounts receivable represents amounts due from our customers including dealers and distributors that purchase our products for redistribution, medical practitioners, clinics, hospitals, colleges, universities, and sports teams. We believe that our estimate of the allowance for credit losses is adequate based on our historical experience and relationships with our customers. Accounts receivable are generally collected within approximately 40 days of invoicing.
Inventories, net
Inventories, net of reserves, increased $944,000 or 16.9%, to $6,538,000 as of December 31, 2024, compared to $5,594,000 as of June 30, 2024. The increase was primarily due to an increase in inventory purchases in order to increase safety stock levels of key products. We believe that our allowance for inventory obsolescence is adequate based on our analysis of inventory, sales trends, and historical experience.
Accounts Payable
Accounts payable increased approximately $751,000 or 27.7%, to $3,463,000 as of December 31, 2024, from $2,712,000 as of June 30, 2024. The increase was driven primarily by an increase in inventory purchases and timing of payments.
Line of Credit
The outstanding balance of the line of credit was $2,355,000 as of December 31, 2024, compared to $2,122,000 as of June 30, 2024.
Finance Lease Liability
Finance lease liability as of December 31, 2024 and June 30, 2024 totaled approximately $1,582,000 and $1,732,000, respectively. Our finance lease liability consists primarily of our Utah building lease. In conjunction with the sale and leaseback of our Utah building in August 2014, we entered into a 15-year lease, classified as a finance lease, originally valued at $3,800,000. The building lease asset is amortized on a straightline basis over 15 years at approximately $252,000 per year. Total accumulated amortization related to the leased building is approximately $2,624,000 at December 31, 2024. The sale generated a profit of $2,300,000, which is being recognized straightline over the life of the lease at approximately $150,000 per year as an offset to amortization expense. The balance of the deferred gain as of December 31, 2024, is $702,000. Lease payments, currently approximately $33,000, are payable monthly and increase annually by approximately 2% per year over the life of the lease. Imputed interest for the three and six months ended December 31, 2024 was approximately $22,000 and $45,000, respectively. In addition to the Utah building, we have certain equipment leases that we have determined are finance leases.
Operating Lease Liability
Operating lease liability as of December 31, 2024 and June 30, 2024 totaled approximately $2,741,000 and $2,834,000, respectively. Our operating lease liability consists primarily of building leases for office, manufacturing, and warehouse space.
Deferred Income Tax Assets
A valuation allowance is required when there is significant uncertainty as to the realizability of deferred income tax assets. The ability to realize deferred income tax assets is dependent upon our ability to generate sufficient taxable income within the carryforward periods provided for in the tax law for each tax jurisdiction. We have determined that we do not meet the "more likely than not" threshold that deferred income tax assets will be realized. Accordingly, a valuation allowance is required. Any reversal of the valuation allowance in future periods will favorably impact our results of operations in the period of reversal. As of December 31, 2024 and June 30, 2024, we recorded a full valuation allowance against our net deferred income tax assets.
Stock Repurchase Plans
We have a stock repurchase plan available to us at the discretion of the Board of Directors. Approximately $449,000 remained of this authorization as of December 31, 2024. No purchases have been made under this plan since September 2011.
Off-Balance Sheet Arrangements
As of December 31, 2024, we had no offbalance sheet arrangements.
Critical Accounting Policies
The preparation of our financial statements requires that we make estimates and judgments. We base these on historical experience and on other assumptions that we believe to be reasonable. Our critical accounting policies are discussed in Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations" section of our Annual Report on Form 10K for the fiscal year ended June 30, 2024. There have been no material changes to the critical accounting policies previously disclosed in that report.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
There have been no material changes from the information presented for the fiscal year ended June 30, 2024.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures that are designed to ensure that information that is required to be disclosed in our reports filed under the Securities Exchange Act of 1934, or Exchange Act, is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to management, including our Chief Executive Officer (principal executive officer) and Chief Financial Officer (principal financial and accounting officer), as appropriate, to allow timely decisions regarding any required disclosure. In designing and evaluating these disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures.
Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the design and operation of our disclosure controls and procedures, as such term is defined under Rule 13a15(e) promulgated under the Exchange Act, as of December 31, 2024. Based on this evaluation, our principal executive officer and principal financial officer concluded that as of December 31, 2024, our disclosure controls and procedures were effective, at a reasonable assurance level, to ensure that information we are required to disclose in the reports we file or submit under the Exchange Act is (a) recorded, processed, summarized, and reported, within the time periods specified in the SEC's rules and forms and (b) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the quarter ended December 31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
Item 1. Legal Proceedings
None.
Item 1A.
The risk factors described in our Annual Report on Form 10K for the fiscal year ended June 30, 2024 have not materially changed.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
None.
Item 5. Other Information
During the fiscal quarter ended December 31, 2024, none of our directors or officers informed us of the adoption, modification or termination of a "Rule 10b5-1 trading arrangement" or "non-Rule 10b5-1 trading arrangement," as those terms are defined in Regulation S-K, Item 408.
Item 6. Exhibits
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| |
DYNATRONICS CORPORATION |
| |
|
|
| Date: February 14, 2025 |
By: |
/s/ Brian D. Baker |
| |
|
Brian D. Baker |
| |
|
President, Chief Executive Officer |
| |
|
(Principal Executive Officer) |
| |
|
|
| |
By: |
/s/ Gabe Ellwein |
| |
|
Gabe Ellwein |
| |
|
Chief Financial Officer |
| |
|
(Principal Financial Officer, and Principal Accounting Officer) |
